1Chou, R. Clinical Guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain: what are the key messages for clinical practice? Pol Arch Med Wewn 2009; 119: 469–77.
2Von Korff, M, Saunders, K, Thomas Ray, G, Boudreau, D, Campbell, C, Merrill, J, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain 2008; 24: 521–7.
3Scherrer, JF, Salas, J, Copeland, LA, Stock, EM, Ahmedani, BK, Sullivan, MD, et al. Prescription opioid duration, dose, and increased risk of depression in 3 large patient populations. Ann Fam Med 2016; 14: 54–62.
4Vanderlip, ER, Sullivan, MD, Edlund, MJ, Martin, BC, Fortney, J, Austen, M, et al. National study of discontinuation of long-term opioid therapy among veterans. Pain 2014; 155: 2673–94.
5Martin, BC, Fan, MY, Edlund, MJ, Devries, A, Brennan-Braden, J, Sullivan, MD. Long-term chronic opioid therapy discontinuation rtes from the TROUP study. J Gen Intern Med 2011; 26: 1450–7.
6Scherrer, JF, Salas, J, Sullivan, MD, Schneider, FD, Bucholz, KK, Burroughs, T, et al. The influence of prescription opioid use duration and dose on development of treatment resistant depression. Prev Med 2016; 91: 110–6.
7Scherrer, JF, Svrakic, DM, Freedland, KE, Chrusciel, T, Balasubramanian, S, Bucholz, KK, et al. Prescription opioid analgesics increase the risk of depression. J Gen Intern Med 2014; 29: 491–9.
8Sullivan, MD. Why does depression promote long-term opioid use? Pain 2016; 157: 2395–6.
9Kroenke, K, Bair, MJ, Damush, TM, Wu, J, Hoke, S, Sutherland, J, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. JAMA 2009; 301: 2099–110.
10Kroenke, K, Wu, J, Bair, MJ, Krebs, EE, Damush, TM, Tu, W. Reciprocal relationship between pain and depression: a 12-month longitudinal analysis in primary care. J Pain 2011; 12: 964–73.
11Vowles, KE, Witkiewitz, K, Levell, J, Sowden, G, Ashworth, J. Are reductions in pain intensity and pain-related distress necessary? An analysis of within-treatment change trajectories in relation to improved functioning following interdisciplinary acceptance and commitment therapy for adults with chronic pain. J Consult Clin Psychol 2017; 85: 87–98.
12Ho, SC, Chong, HY, Chaiyakunapruk, N, Tangiisuran, B, Jacob, SA. Clinical and economic impact of non-adherence to antidepressants in major depressive disorder: a systematic review. J Affect Disord 2016; 193: 1–10.
13Akerblad, AC, Bengtsson, F, von Knorring, L, Ekselius, L. Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int Clin Psychopharmacol 2006; 21: 117–24.
14Kroenke, K, Spitzer, RL, Williams, JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606–13.
15World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD–9). WHO, 1978.
16Frayne, SM, Miller, DR, Sharkansky, EJ, Jackson, VW, Wang, F, Halanych, JH, et al. Using administrative data to identify mental illness: what approach is best? Am J Med Qual 2010; 25: 42–50.
17Solberg, LI, Engebretson, KI, Sperl-Hillen, JM, Hroscikoski, MC, O'Connor, PG. Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease and depression. Am J Med Qual 2006; 21: 238–45.
18National Committee for Quality Assurance. The State of Health Care Quality. National Committee for Quality Assurance, 2013.
19Hess, LM, Raebel, MA, Conner, DA, Malone, DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40: 1280–8.
20Cramer, JA, Roy, A, Burrell, A, Fairchild, CJ, Fuldeore, MJ, Ollendorf, DA, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44–7.
22Quinn, PD, Hur, K, Chang, Z, Krebs, EE, Bair, MJ, Scott, EL, et al. Incident and long-term opioid therapy among patients with psychiatric conditions and medications: a national study of commercial health care claims. Pain 2017; 158: 140–8.
23Thakore, JH. Physical Consequences of Depression. Wrightson Biomedical Publishing, 2001.
24Seal, KH, Shi, Y, Cohen, G, Cohen, BE, Maguen, S, Krebs, EE, et al. Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. JAMA 2012; 307: 940–7.
25Correa, D, Farney, RJ, Chung, F, Prasad, A, Lam, D, Wong, J. Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations. Anesth Analg 2015; 120: 1273–85.
26O'Rourke, TK Jr, Wosnitzer, MS. Opioid-induced androgen deficiency (OPIAD): diagnosis, management, and literature review. Curr Urol Rep 2016; 17: 76.
27Dobscha, SK, Morasco, BJ, Kovas, AE, Peters, DM, Hart, K, McFarland, BH. Short-term variability in outpatient pain intensity scores in a national sample of older veterans with chronic pain. Pain Med 2015; 16: 855–65.
28Cole, SR, Hernan, MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168: 656–64.
29Curtis, LH, Hammill, BG, Eisenstein, EL, Kramer, JM, Anstrom, KJ. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007; 45 (10 Supl 2): S103–7.
30Harder, VS, Stuart, EA, Anthony, JC. Propsensity score techinques and the assessment of measure covariate balance to test causal associations in psychological research. Psychol Methods 2010; 15: 234–49.
31Kilpatrick, RD, Gilbertson, D, Brookhart, MA, Polley, E, Rothman, KJ, Bradbury, BD. Exploring large weight deletion and the ability to balance confounders when using inverse probability of treatment weighting in the presence of rate treatment decisions. Pharmacoepidemiol Drug Saf 2013; 22: 111–21.
32Rosenbaum, PR, Rubin, DB. The central role of the prospensity score in observational studies for causal effects. Biometrika 1983; 70; 41–55.
33Xu, S, Ross, C, Raebel, MA, Shetterly, S, Blanchette, C, Smith, D. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 2010; 13: 273–7.
34Austin, P, Stuart, E. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015; 34: 3661–79.
35Sturmer, T, Wyss, R, Glynn, RJ, Brookhart, MA. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med 2014; 275: 570–80.
36Austin, P. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28: 3083–107.
37Howe, CQ, Sullivan, MD. The missing ‘P’ in pain management: how the current opioid epidemic highlights the need for psychiatric services in chronic pain care. Gen Hosp Psychiatry 2014; 36: 99–104.
38Berna, C, Kulich, RJ, Rathmell, JP. Tapering long term opioid therapy in chronic noncancer pain: evidence and recommendations for everyday practice. Mayo Clin Proc 2015; 90: 828–42.
39Bitton, A, Choudhry, NK, Matlin, OS, Swanton, K, Shrank, WH. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med 2013; 126: 357.e7–e27.
40Scherrer, JF, Salas, J, Copeland, LA, Stock, EM, Schneider, FD, Sullivan, M, et al. Increased risk of depression recurrence after initiation of prescription opioids in noncancer pain patients. J Pain 2016; 17: 473–82.
41Skljarevski, V, Desaiah, D, Liu-Seifert, H, Zhang, Q, Chappell, AS, Detke, MJ, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine 2010; 35: E578–E85.
42Atkinson, JH, Patel, SM, Meyer, JM, Slater, MA, Zisook, S, Capparelli, E. Is there a therapeutic window with some antidepressants for analgesic response? Curr Pain Headache Rep 2009; 13: 93–9.